Bamco Inc. NY Acquires 105,000 Shares in Roivant Sciences Ltd.

The institutional investor added to its stake in the biopharmaceutical company during the third quarter.

Mar. 17, 2026 at 7:35am

Got story updates? Submit your updates here. ›

Bamco Inc. NY, an institutional investor, acquired a new stake of 105,000 shares in Roivant Sciences Ltd. (NASDAQ:ROIV) during the third quarter of 2026, according to a filing with the Securities and Exchange Commission. The shares were valued at approximately $1,589,000.

Why it matters

This acquisition represents a significant investment by Bamco Inc. NY in Roivant Sciences, a biopharmaceutical company focused on developing innovative therapies across various therapeutic areas. The move suggests the institutional investor sees potential in Roivant's pipeline and future growth prospects.

The details

Bamco Inc. NY acquired the 105,000 shares of Roivant Sciences as part of its investment strategy during the third quarter. The shares were valued at around $1,589,000. In addition to Bamco, other hedge funds and institutional investors have also been buying and selling Roivant shares in recent quarters, indicating ongoing interest in the company.

  • Bamco Inc. NY acquired the 105,000 shares of Roivant Sciences during the third quarter of 2026.

The players

Bamco Inc. NY

An institutional investor that acquired a new stake of 105,000 shares in Roivant Sciences Ltd.

Roivant Sciences Ltd.

A biopharmaceutical company focused on developing innovative therapies across various therapeutic areas.

Got photos? Submit your photos here. ›

The takeaway

Bamco Inc. NY's acquisition of a significant stake in Roivant Sciences suggests the institutional investor sees potential in the biopharmaceutical company's future growth and pipeline development. This move highlights the ongoing interest from hedge funds and other institutional investors in Roivant Sciences as it continues to advance its therapeutic programs.